Navigating Clonal Hematopoiesis in Liquid Biopsy: Insights from Real-World Cases

Liquid biopsy (LBx) has emerged as a non-invasive genomic profiling approach to guide treatment selection and monitor resistance in cancer, especially when access to tumor tissue is limited. However, one of the key challenges of LBx is distinguishing somatic variants from clonal hematopoiesis (CH)-derived variants, which can occur in prognostically important genes and confound variant interpretation.

In this webinar, Dr. Keller and Dr. Fares (IUCT Oncopole, France) will explore real-world clinical cases where insights from MSK-ACCESS® powered with SOPHiA DDM™ helped inform treatment decisions. The decentralized liquid biopsy solution integrates matched white blood cell (WBC) DNA sequencing to filter out CH and germline variants, increasing confidence in the somatic origin of detected alterations.

By attending this session, you will gain:

• Practical insights into the clinical utility of liquid biopsy
• An understanding of how CH confounds variant interpretation
• Real-world examples of how matched tumor-normal analysis helps inform decision-making